['hiv infection']
['monopi - boosted lopinavir or boosted darunavir', 'bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine']

        Inclusion Criteria:

          -  HIV infection on second line treatment in the 2lady trial for at least 48 weeks

          -  VL ≤ 200 copies/ml since at least 6 months

          -  No change in ART in the last 3 months previous to the study

          -  CD4> 100 cells/ml

          -  Signed informed consent

          -  Adherence >90

        Exclusion Criteria:

          -  Previous viral failure (at least 2 consecutive HIV RNA >1000 copies/ml) while
             receiving a PI

          -  Ongoing pregnancy and breast feeding women

          -  HBsAg positive patients

          -  opportunistic infection or any severe or progressive disease ongoing or treated in the
             3 months before screening

          -  Subject who in the investigator's opinion is unable to complete the study

          -  History or symptoms of HIV encephalopathy
      